This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McQuellon, R. P. Articles by Levine, E. A. Search for Related Content PubMed PubMed Citation Articles by McQuellon, R. P. Articles by Levine, E. A.

Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

¹ Department of Internal Medicine, Section of Hematology and Oncology, Wake Forest University, School of Medicine, Winston-Salem, NC, USA
² Department of Biostatistics, Wake Forest University, School of Medicine, Winston-Salem, NC, USA
³ Department of Surgical Oncology, Wake Forest University, School of Medicine, Winston-Salem, NC, USA
⁴ Comprehensive Cancer Center of Wake Forest University, Medical Center Blvd., Winston-Salem, NC 27157-1082, USA

Correspondence: Address correspondence and reprint requests to: Richard P. McQuellon; E-mail: rmcquell{at}wfubmc.edu

Background: Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for peritoneal carcinomitosis (PC) is an aggressive treatment designed to alleviate symptoms and prolong life. It is associated with physical and psychological morbidity. The purpose of this study was to monitor health outcomes related to treatment.

Methods: Patients completed a questionnaire before and after surgery at 3, 6 and 12 months. The questionnaire consisted of basic demographic items as well as the Functional Assessment of Cancer Therapy–Colon Scale (FACT-C), SF-36 Medical Outcomes Study Health Survey, Center for Epidemiologic Studies–Depression Scale (CES-D), Brief Pain Inventory–Short Form, and ECOG Performance Status Rating. Time trends were assessed with mixed models (SAS PROC MIXED) so as to use all data and to account for missing data.

Results: Ninety-six patients (49% females, 9% African Americans) of an average age of 52.9 (SD = 12.5) years were assessed before surgery. PC originated in primary lesions of the appendix (n = 36); colon/rectum (n = 24); mesothelium (n = 9); ovary (n = 5); stomach (n = 4); and miscellaneous (n = 18). Quality of life (QOL) and pain scores improved from baseline to 12 months. Physical functioning changed over the 12-month study period with improvement recorded at 6 months. The percentage of patients reporting significant depressive symptom at each time point was; baseline= 32%; 3 months= 19%; 6 & 12 months= 24%.

Conclusions: Acceptable QOL, return of functional status, and reduced pain can be attained between 3 and 6 months following treatment although some deficits in general health remain. Depressive symptoms are common and should be monitored.

Key Words: Health outcomes • Intraperitoneal hyperthermic chemotherapy (IPHC)

This article has been cited by other articles:

				R. P. McQuellon, G. B. Russell, P. Shen, J. H. Stewart IV, W. Saunders, and E. A. Levine Survival and Health Outcomes After Cytoreductive Surgery With Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Appendiceal Origin Ann. Surg. Oncol., January 1, 2008; 15(1): 125 - 133. [Abstract] [Full Text] [PDF]